(Q56908635)

https://api.crossref.org/works/10.1016%2FS0065-3519%2897%2980006-7

7 January 2021

Phenotypic correction of factor IX deficiency in skin fibroblasts of hemophilic dogs

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3519%2897%2980006-7

7 January 2021

Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3519%2897%2980006-7

7 January 2021

Lack of expression from a retroviral vector after transduction of murine hematopoietic stem cells is associated with methylation in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3519%2897%2980006-7

7 January 2021

High-efficiency receptor-mediated delivery of small and large (48 kilobase gene constructs using the endosome-disruption activity of defective or chemically inactivated adenovirus particles.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3519%2897%2980006-7

7 January 2021

Gene therapy via primary myoblasts: long-term expression of factor IX protein following transplantation in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3519%2897%2980006-7

7 January 2021

Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3519%2897%2980006-7

7 January 2021

Helper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3519%2897%2980006-7

7 January 2021

Gene therapy for hemophilia A: production of therapeutic levels of human factor VIII in vivo in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3519%2897%2980006-7

7 January 2021

Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3519%2897%2980006-7

7 January 2021

Canine hemophilia B resulting from a point mutation with unusual consequences

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3519%2897%2980006-7

7 January 2021

Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3519%2897%2980006-7

7 January 2021

Characterization of the human factor VIII gene.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3519%2897%2980006-7

7 January 2021

A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3519%2897%2980006-7

7 January 2021

Genetics of adeno-associated virus: isolation and preliminary characterization of adeno-associated virus type 2 mutants

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3519%2897%2980006-7

7 January 2021

Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3519%2897%2980006-7

7 January 2021

Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4Ig administration

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3519%2897%2980006-7

7 January 2021

In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogs

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3519%2897%2980006-7

7 January 2021

In vivo gene therapy of hemophilia B: sustained partial correction in factor IX-deficient dogs

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3519%2897%2980006-7

7 January 2021

Site-specific integration by adeno-associated virus

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3519%2897%2980006-7

7 January 2021

Gene therapy: adenovirus vectors.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3519%2897%2980006-7

7 January 2021

Efficient transfection of primary cells in a canine hemophilia B model using adenovirus-polylysine-DNA complexes

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3519%2897%2980006-7

7 January 2021

An evaluation of receptor-mediated gene transfer using synthetic DNA-ligand complexes

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3519%2897%2980006-7

7 January 2021

Absence of anti-human immunodeficiency virus types 1 and 2 seroconversion after the treatment of hemophilia A or von Willebrand's disease with pasteurized factor VIII concentrate

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3519%2897%2980006-7

7 January 2021

Absence of hepatitis after treatment with a pasteurized factor VIII concentrate in patients with hemophilia and no previous transfusions

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3519%2897%2980006-7

7 January 2021

An alternative approach to somatic cell gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3519%2897%2980006-7

7 January 2021

Haemophilia A: database of nucleotide substitutions, deletions, insertions and rearrangements of the factor VIII gene

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3519%2897%2980006-7

7 January 2021

Response to infusions of polyelectrolyte fractionated human factor VIII concentrate in human haemophilia A and von Willebrand's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3519%2897%2980006-7

7 January 2021

Structure of human factor VIII

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3519%2897%2980006-7

7 January 2021

Successful expression of human factor IX following repeat administration of adenoviral vector in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3519%2897%2980006-7

7 January 2021

Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3519%2897%2980006-7

7 January 2021

Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3519%2897%2980006-7

7 January 2021

Expression of human factor IX in mice after injection of genetically modified myoblasts

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3519%2897%2980006-7

7 January 2021

Expression of human factor IX in rat capillary endothelial cells: toward somatic gene therapy for hemophilia B

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3519%2897%2980006-7

7 January 2021

Nucleotide sequence of the gene for human factor IX (antihemophilic factor B)

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3519%2897%2980006-7

7 January 2021

In vivo production of human factor VII in mice after intrasplenic implantation of primary fibroblasts transfected by receptor-mediated, adenovirus-augmented gene delivery

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3519%2897%2980006-7

7 January 2021